Risk-sharing in the Pharmaceutical Industry [electronic resource] : The Case of Out-licensing / by Gerrit Reepmeyer.

Por: Reepmeyer, Gerrit [author.]Tipo de material: TextoTextoSeries Contributions to Management ScienceEditor: Heidelberg : Physica-Verlag HD, 2006Descripción: XIV, 297 p. 70 illus. online resourceTipo de contenido: text Tipo de medio: computer Tipo de portador: online resourceISBN: 9783790816686Trabajos contenidos: SpringerLink (Online service)Tema(s): Economics | Technology | Economics/Management Science | Technology ManagementFormatos físicos adicionales: Sin títuloClasificación CDD: 658.514 Clasificación LoC:HD28-70Recursos en línea: de clik aquí para ver el libro electrónico
Contenidos:
Springer eBooksResumen: The costs of developing a new drug have reached record levels in the pharmaceutical industry. As any failure of a new drug candidate can lead to significant losses, many pharmaceutical companies are looking for new approaches to reduce their exposure to R&D risks. In this context, the book deals with the topic of out-licensing as a novel form of risk-sharing collaborations. The phenomenon of out-licensing is illustrated by three major case studies of Novartis, Schering and Roche as well as several smaller case studies. In addition, the Noble Prize awarded economic theory of Adverse Selection is applied to analyze the topic theoretically. The gained insights allow identifying the critical parameters of out-licensing collaborations and thereby provide R&D managers with recommendations on how to conclude and manage this type of deals more effectively.
Etiquetas de esta biblioteca: No hay etiquetas de esta biblioteca para este título. Ingresar para agregar etiquetas.
    Valoración media: 0.0 (0 votos)
No hay ítems correspondientes a este registro

Key Issues in Managing Pharmaceutical Innovation -- Risk-sharing as New Paradigm in Pharma R&D Collaborations -- Case Studies on Risk-sharing in Pharma R&D Collaborations -- Characteristics of Risk-sharing in Pharma R&D Collaborations -- Theoretical Basis for Risk-sharing in Pharma R&D Collaborations -- Managerial Recommendations for Risk-sharing in Pharma R&D Collaborations -- Conclusion.

The costs of developing a new drug have reached record levels in the pharmaceutical industry. As any failure of a new drug candidate can lead to significant losses, many pharmaceutical companies are looking for new approaches to reduce their exposure to R&D risks. In this context, the book deals with the topic of out-licensing as a novel form of risk-sharing collaborations. The phenomenon of out-licensing is illustrated by three major case studies of Novartis, Schering and Roche as well as several smaller case studies. In addition, the Noble Prize awarded economic theory of Adverse Selection is applied to analyze the topic theoretically. The gained insights allow identifying the critical parameters of out-licensing collaborations and thereby provide R&D managers with recommendations on how to conclude and manage this type of deals more effectively.

No hay comentarios en este titulo.

para colocar un comentario.